Kolexia
Lambert Thierry Médecine générale
Lambert Thierry
Médecine générale
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
123 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hémophilie A Hémorragie Hémophilie B Hémarthrose Afibrinogénémie Troubles héréditaires de la coagulation sanguine Hémorragies intracrâniennes Hématome Maladies articulaires

Collaborateurs

Voir plus
Negrier Claude
Negrier Claude
Hôpital Louis Pradel, Bron, France
D'Oiron Roseline
D'Oiron Roseline
Hôpital Bicêtre, Le Kremlin-Bicêtre, France
Harroche-Angel Annie
Harroche-Angel Annie
Hôpital Necker Enfants Malades, Paris, France
Borel-Derlon Annie
Borel-Derlon Annie
Hôpital Côte de Nacre, Caen, France

Industries

Voir plus
Roche
20 collaboration(s)
Dernière en 2023
Sobi
13 collaboration(s)
Dernière en 2022
A+A
8 collaboration(s)
Dernière en 2022
CSL Behring
7 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada.
Research and practice in thrombosis and haemostasis   20 novembre 2023
Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
Haemophilia : the official journal of the World Federation of Hemophilia   19 juin 2023
TRANSHEMO: Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia - TRANSHEMO
Essai Clinique (Assistance publique - Hôpitaux de Marseille)   13 février 2023
PO326 QUALITATIVE RESEARCH EXPLORING LIFE CHANGES IN PATIENTS LIVING WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS TREATED WITH EMICIZUMAB
16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023, Manchester   05 février 2023
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
Blood advances   20 décembre 2022
HAVEN 4: A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks (Q4W) in Patients With Hemophilia A
Essai Clinique (Roche)   13 décembre 2022
Conception et suivi de l’implantation nationale de la formation HEMOPHAR, destinée aux pharmaciens d’officine prenant en charge des patients traités par emicizumab
Le Pharmacien Clinicien   01 décembre 2022
HAVEN 3: A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors
Essai Clinique (Roche)   19 octobre 2022
Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis.
Haemophilia : the official journal of the World Federation of Hemophilia   14 avril 2022
Whole Blood Impedance Aggregometry: A Usefool Tool but Still Not the Gold Standard
Special Issue: Abstracts of the ISTH 2021 Virtual Congress of the International Society of Thrombosis and Haemostasis, July 17–21, 2021   07 octobre 2021